Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Johnson & Johnson : Women win landmark class action against Johnson & Johnson in Australia

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/21/2019 | 02:21am EST

Sydney, Australia, Nov 21 (EFE).- More than 1,350 women who have suffered debilitating side effects of pelvic mesh implants won a landmark class action suit against multinational giant Johnson & Johnson on Thursday in Sydney, Australia.

The case, which began in 2012, has been described by the prosecution as the biggest class action concerning women's health in Australia's history.

The Federal Court of Australia held the behavior of the American multinational and its subsidiary Ethicon as "negligent" underlining that "the risks were known, not insignificant, and on the respondents' own admission, could cause significant and serious harm if they eventuated."

Women have said that the pelvic implants - mesh or tape surgically placed to resolve pelvic floor damage such as that commonly caused during childbirth - have caused debilitating problems such as urinary incontinence, chronic pain, including during sex, infections and a significant psychological toll.

The court heard that three women who brought the class action - Kathryn Gill, Diane Dawson and Ann Sanders - described their symptoms ranging from "pain... so bad she struggles to breathe," "excruciating pain across her buttocks, pain deep inside her vagina, and pain that radiated down her leg," and "chronic pain and multiple other symptoms. Her enjoyment of life has been substantially diminished" to "frightened about what the future holds."

The court judgment said one or more surgical procedures may be required to remove mesh that had eroded, and that "removal carried the risk of new complications or of aggravating existing complications."

"I found that the respondents were liable to compensate any applicant and/or group member who suffered an injury because of the defect for the amount of the loss and damage she sustained as a result of that injury," Judge Anna Katzmann said.

She granted the parties time to read the judgment and reach an agreement, and "each of the applicants will need to make an election as to whether she wishes to receive damages under the Trade Practices Act or at common law" before her final decision in February next year.

The compensation is expected to reach millions of dollars given that some 8,000 women are estimated to have been affected, according to Shine Lawyers, a legal firm representing the women in the case.

"It has been a long journey to get here through this legal process. We have fought hard to have these women's voices heard, as they've struggled with the chronic pain and complications from their mesh and tape implants," Shine Lawyers' Special Counsel for Class Actions Rebecca Jancauskas said in a statement.

Thousands of women in the United States, as well as the United Kingdom and Canada, among others, have sued Johnson & Johnson over side effects of pelvic implants. EFE

© 2019 EFE News Services (U.S.) Inc., source EFE Ingles

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
12/11JOHNSON & JOHNSON : Janssen Pharmaceutical - DARZALEX Regimen Shows Significant ..
AQ
12/10JOHNSON & JOHNSON : appeals Oklahoma judge's opioid ruling
AQ
12/10JOHNSON & JOHNSON : to Host Investor Conference Call on Fourth-Quarter Results
PR
12/10JOHNSON & JOHNSON : Vaccine Regimen from Janssen and Bavarian Nordic to Support ..
AQ
12/10JOHNSON & JOHNSON : Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-..
AQ
12/10JOHNSON & JOHNSON : Janssen Pharmaceutical - DARZALEX Shows Overall Survival Ben..
AQ
12/10AMGEN : Phase 3 Study Combining Kyprolis, Darzalex Met Primary Endpoint
DJ
12/09WISETECH GLOBAL LTD (ASX : WTC) Acquires South Korean Solutions Provider, Ready ..
AQ
12/09JOHNSON & JOHNSON : Janssen to Acquire Investigational Bermekimab from XBiotech
PU
12/09XBiotech Shares Jump After Selling Bermekimab to Janssen
DJ
More news
Financials (USD)
Sales 2019 82 175 M
EBIT 2019 25 638 M
Net income 2019 17 334 M
Debt 2019 6 823 M
Yield 2019 2,66%
P/E ratio 2019 21,6x
P/E ratio 2020 19,1x
EV / Sales2019 4,61x
EV / Sales2020 4,33x
Capitalization 372 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 149,90  $
Last Close Price 141,38  $
Spread / Highest target 22,4%
Spread / Average Target 6,03%
Spread / Lowest Target -8,76%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON9.52%372 094
ROCHE HOLDING AG24.22%261 287
MERCK AND COMPANY16.73%227 076
PFIZER-12.19%212 123
NOVARTIS22.85%210 097
BRISTOL-MYERS SQUIBB COMPANY23.01%149 606